title: In-hospital major cardiovascular events between STEMI receiving thrombolysis therapy and primary PCI.
abstract: OBJECTIVE
  to compare the in-hospital major cardiovascular events between thrombolysis therapy and primary percutaneous coronary intervention (PCI) in patients with ST-elevation acute myocardial infarction (STEMI.
  
  
  METHODS
  the study design is retrospective cohort. Medical record of patients with STEMI onset<12 hour receiving thrombolysis treatment or primary PCI in Dr. Sardjito Hospital Yogyakarta between January 2008 and March 2010 are evaluated. The primary outcome is major cardiovascular events which comprise cardiovascular death, reinfarction and stroke during hospitalisation. The secondary outcomes are post infarction angina pectoris, heart failure, cardiogenic shock and bleeding.
  
  
  RESULTS
  among 78 patients with thrombolysis and 53 patients with primary PCI, in-hospital major cardiovascular events do not differ significantly (10.3% versus 9.4%; RR 1.09, 95%CI 0.33-3.55; p=0.87). Post infarction angina pectoris is 7% versus 3.8% (RR 2.51, 95%CI 0.50-12.60; p=0.24). The incidence of heart failure is significantly higher in thrombolysis (17.9% versus 5.7%; RR 3.64, 95%CI 0.99-13.38; p=0.04), primary PCI reduces 68.1% relative risk to develop acute heart failure in STEMI. The incidence of cardiogenic shock is not different. Major and minor bleeding do not differ significantly either.
  
  
  CONCLUSIONS
  the in-hospital major cardiovascular events between STEMI receiving thrombolysis therapy and primary PCI is not significantly different. Heart failure is significantly higher in thrombolysis therapy and the primary PCI reduces the risk.
authors: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Gadjah Mada - Sardjito Hospital, Yogyakarta, Indonesia.
authors: Irsad A
authors: IA
authors: Arso
authors: Budi Y
authors: BY
authors: Setianto
authors: Nahar
authors: N
authors: Taufiq
authors: Anggoro B
authors: AB
authors: Hartopo
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000209:etiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000209:etiology; D006470:Hemorrhage / Q000209:etiology; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D012008:Recurrence; D012189:Retrospective Studies; D012770:Shock, Cardiogenic / Q000209:etiology; D020521:Stroke / Q000209:etiology
chemical_list: D005343:Fibrinolytic Agents